What is HC Wainwright’s Estimate for APLS FY2024 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research report issued on Wednesday, November 6th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($1.79) for the year, down from their prior forecast of ($1.67). HC Wainwright currently has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.55) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.73) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at $0.88 EPS and FY2028 earnings at $2.61 EPS.

Several other research firms have also commented on APLS. The Goldman Sachs Group dropped their target price on Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday. William Blair initiated coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating for the company. Jefferies Financial Group reissued a “buy” rating and issued a $80.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Evercore ISI upgraded shares of Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Finally, Citigroup cut their price target on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $51.06.

Apellis Pharmaceuticals Trading Down 0.3 %

Shares of APLS opened at $28.74 on Friday. Apellis Pharmaceuticals has a fifty-two week low of $24.34 and a fifty-two week high of $73.80. The company has a market capitalization of $3.50 billion, a PE ratio of -10.49 and a beta of 0.87. The stock has a fifty day moving average of $31.19 and a two-hundred day moving average of $37.14. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The firm had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same period in the prior year, the firm earned ($1.17) EPS. The business’s quarterly revenue was up 78.3% on a year-over-year basis.

Insider Buying and Selling

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of APLS. Wolverine Asset Management LLC purchased a new stake in Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at approximately $56,000. KBC Group NV grew its position in shares of Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after buying an additional 679 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Apellis Pharmaceuticals in the first quarter worth $89,000. Finally, nVerses Capital LLC raised its holdings in Apellis Pharmaceuticals by 300.0% in the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after acquiring an additional 2,100 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).